{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=81", "query": { "intervention": "Cellular analysis", "page": 81 }, "page_size": 10 }, "pagination": { "page": 81, "page_size": 10, "total_count": 2010, "total_pages": 201, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=82&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Cellular+analysis&page=80&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-09T03:11:35.721Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00412594", "title": "Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hairy Cell Leukemia", "Recurrent Hairy Cell Leukemia" ], "interventions": [ { "name": "Cladribine", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2004-06-10", "completion_date": "2027-06-30", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00412594" }, { "nct_id": "NCT00019604", "title": "Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Liver Cancer", "Metastatic Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "radiofrequency ablation", "type": "PROCEDURE" }, { "name": "radionuclide imaging", "type": "PROCEDURE" }, { "name": "ultrasound imaging", "type": "PROCEDURE" }, { "name": "fludeoxyglucose F 18 (FDG-PET)", "type": "RADIATION" }, { "name": "gadopentetate dimeglumine", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "RADIATION" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "1998-08", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2017-02-03", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00019604" }, { "nct_id": "NCT00667017", "title": "RFT5-dgA Immunotoxin in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "RFT5-dgA immunotoxin", "type": "BIOLOGICAL" }, { "name": "fluorescence activated cell sorting", "type": "OTHER" }, { "name": "immunohistochemistry staining method", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "University of Texas Southwestern Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 1, "start_date": "2008-11-07", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2018-12-14", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00667017" }, { "nct_id": "NCT00363649", "title": "Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "GM-K562 cell vaccine", "type": "BIOLOGICAL" }, { "name": "Interferon alfa", "type": "BIOLOGICAL" }, { "name": "Sargramostim", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 36, "start_date": "2006-09", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2018-11-13", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00363649" }, { "nct_id": "NCT03348748", "title": "Stereotactic Body Radiation Therapy Followed by Surgery in Treating Patients With Stage I-IIIA Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Stage I Non-Small Cell Lung Cancer AJCC v7", "Stage IA Non-Small Cell Lung Carcinoma AJCC v7", "Stage IB Non-Small Cell Lung Carcinoma AJCC v7", "Stage II Non-Small Cell Lung Cancer AJCC v7", "Stage IIA Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIB Non-Small Cell Lung Carcinoma AJCC v7", "Stage IIIA Non-Small Cell Lung Cancer AJCC v7" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Stereotactic Body Radiation Therapy", "type": "DRUG" }, { "name": "Thoracic Surgical Procedure", "type": "PROCEDURE" } ], "intervention_types": [ "OTHER", "DRUG", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2017-12-18", "completion_date": "2025-11-10", "has_results": false, "last_update_posted_date": "2026-04-02", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03348748" }, { "nct_id": "NCT00470184", "title": "Oxaliplatin, Capecitabine, and Radiation Therapy in Patients Undergoing Surgery for Stage II, III, IV Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer" ], "interventions": [ { "name": "capecitabine", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "microarray analysis", "type": "GENETIC" }, { "name": "reverse transcriptase-polymerase chain reaction", "type": "GENETIC" }, { "name": "adjuvant therapy", "type": "PROCEDURE" }, { "name": "biopsy", "type": "PROCEDURE" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" }, { "name": "quality-of-life assessment", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "GENETIC", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2006-11", "completion_date": null, "has_results": true, "last_update_posted_date": "2013-11-25", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00470184" }, { "nct_id": "NCT00756106", "title": "MRI Scans in Evaluating the Effects of Radiation Therapy and Chemotherapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Anaplastic Glioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Brain and Central Nervous System Tumors" ], "interventions": [ { "name": "temozolomide", "type": "DRUG" }, { "name": "Imaging biomarker analysis", "type": "OTHER" }, { "name": "Photon Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "OTHER", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2008-07", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2020-05-13", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00756106" }, { "nct_id": "NCT00899704", "title": "Biomarkers in Tissue Samples From Patients Who Have Undergone Neck Dissection for Oral Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "microarray analysis", "type": "GENETIC" }, { "name": "allele-specific oligonucleotide real-time quantitative polymerase chain reaction", "type": "GENETIC" }, { "name": "diagnostic laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 0, "start_date": "2008-03", "completion_date": "2008-03", "has_results": false, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00899704" }, { "nct_id": "NCT01787994", "title": "Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV" ], "interventions": [ { "name": "Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF-T), given via intravenous infusion.", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2012-12", "completion_date": "2017-07", "has_results": false, "last_update_posted_date": "2019-08-30", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01787994" }, { "nct_id": "NCT07695311", "title": "EWSR1 Immunotherapy in Ewing Sarcoma and DSRCT", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Ewing Sarcoma", "Desmoplastic Small Round Cell Tumor" ], "interventions": [ { "name": "EWSR1 immunotherapy", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rabi Hanna", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 24, "start_date": "2026-10", "completion_date": "2030-07", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-11-09T03:11:35.721Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07695311" } ] }